Recent Quotes (30 days)

You have no recent quotes
chg | %

Celgene Corporation  

(Public, NASDAQ:CELG)   Watch this stock  
Find more results for CELG
94.26
+0.41 (0.44%)
Real-time:   3:50p.m. EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 93.80 - 95.72
52 week 88.32 - 147.17
Open 93.90
Vol / Avg. 2.82M/8.39M
Mkt cap 70.90B
P/E 17.97
Div/yield     -
EPS 5.25
Shares 752.18M
Beta 1.49
Inst. own 81%
Apr. 25, 2018
Q1 2018 Celgene Corp Earnings Release (Estimated) - 9:30a.m. EDT - Add to calendar
Mar. 14, 2018
Celgene Corp at Cowen Health care Conference - 8:40a.m. EDT - Add to calendar
Feb. 21, 2018
Celgene Corp at RBC Capital Markets Healthcare Conference
Feb. 15, 2018
Celgene Corp at Leerink Partners Global Healthcare Conference - Webcast
Jan. 25, 2018
Q4 2017 Celgene Corp Earnings Release
Jan. 25, 2018
Q4 2017 Celgene Corp Earnings Call - Webcast
Jan. 22, 2018
Celgene Corp to Acquire Juno Therapeutics Inc Conference Call - Webcast
Jan. 8, 2018
Celgene Corp at JPMorgan Healthcare Conference - Breakout Session
Jan. 8, 2018
Celgene Corp at JPMorgan Healthcare Conference - Webcast
Dec. 10, 2017
Celgene Corp Analyst and Investor Event at American Society of Hematology Meeting - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec. '17) 2017
Net profit margin 34.11% 32.37%
Operating margin 34.25% 35.78%
EBITD margin - 29.44%
Return on average assets 15.40% 14.46%
Return on average equity 56.82% 62.26%
Employees 7,467 -
CDP Score - B

Address

86 Morris Ave
SUMMIT, NJ 07901-3915
United States - Map
+1-908-6739000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

Officers and directors

Mark J. Alles Chairman of the Board, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Scott A. Smith President, Chief Operating Officer
Age: 55
Bio & Compensation  - Reuters
Peter N. Kellogg Chief Financial Officer, Executive Vice President
Age: 61
Bio & Compensation  - Reuters
Terrie Curran President, Global Inflammation & Immunology Franchise
Age: 48
Bio & Compensation  - Reuters
Michael F. Pehl President, Hematology & Oncology
Age: 52
Bio & Compensation  - Reuters
Rupert J Vessey President - Research and Early Development
Age: 52
Bio & Compensation  - Reuters
Gerald F. Masoudi Executive Vice President, General Counsel and Corporate Secretary
Age: 49
Bio & Compensation  - Reuters
Michael D. Casey Lead Independent Director
Age: 71
Bio & Compensation  - Reuters
Michael W. Bonney Director
Age: 59
Bio & Compensation  - Reuters
Julia A. Haller M.D. Director
Age: 62
Bio & Compensation  - Reuters